The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Bevacizumab (bev) in combination with capecitabine (cape) for the first-line treatment of elderly patients with metastatic colorectal cancer (mCRC): Results of a randomized international phase III trial (AVEX).
David Cunningham
Research Funding - AstraZeneca; Merck KGaA; Roche
Istvan Lang
No relevant relationships to disclose
Vito Lorusso
No relevant relationships to disclose
Janja Ocvirk
Honoraria - Roche
Dongbok Shin
No relevant relationships to disclose
Derek J. Jonker
No relevant relationships to disclose
Stuart Osborne
Employment or Leadership Position - Roche
Niko Alexander Andre
Employment or Leadership Position - Roche
Stock Ownership - Roche
Daniel Waterkamp
Employment or Leadership Position - Roche
Stock Ownership - Roche
Mark P. Saunders
No relevant relationships to disclose